Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Phase 3TerminatedNCT00642226

Helse Stavanger HF34 enrolled

Overview

The purpose of this study is to determine whether pars plana vitrectomy in combination with triamcinolone acetate is effective in the treatment of macular edema due to branch retinal vein occlusion.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Branch Retinal Vein Occlusion Macular Edema

Interventions

Grid LaserPROCEDURE

ETDRS Grid Laser

Vitrectomy and 20 mg triamcinolonePROCEDURE

Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Macular edema secondary to BRVO * Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart * Duration no shorter than 3 months * Duration no longer than 12 months Exclusion Criteria: * Proliferations in study eye * Blod in vitreous cavity * Previous fundus laser treatment * BRVO with over 180˚ of ischemia on FA * Age under 18 * Other eye condition which contribute to relevant loss of visual acuity

Locations (1)

Stavanger University Hospital, Department of Ophthalmology

Stavanger, Norway

Outcomes

Primary Outcomes

Visual acuity (ETDRS)

Time frame: 12 and 36 Months

Secondary Outcomes

Retinal thickening measured on OCT.

Time frame: 12 and 36 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.